WebApr 19, 2024 · About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface … WebApr 13, 2024 · Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) VP Jaye Thompson purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, April 11th.The shares were bought at an average price of $11.87 per share, for a total transaction of $11,870.00. Following the completion of the transaction, the vice president now owns …
Greenwich LifeSciences - GLSI News Today - MarketBeat
WebMar 8, 2024 · Greenwich LifeSciences is getting ready to launch Phase 3 trials for its breast cancer treatment March 8, 2024 By Sarah Smith , Editor-in-Chief, InvestorPlace.com Mar 8, 2024, 3:15 pm EST March 8 ... WebApr 14, 2024 · On Friday, March 10th, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $12.12 per share, with a total value of $12,120.00. crystal ball vs decision tools
Greenwich LifeSciences : Announces Presentation of 5 Year Data …
WebApr 14, 2024 · Greenwich LifeSciences, Inc. ( NASDAQ:GLSI – Get Rating) CEO Snehal Patel acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, April … WebApr 11, 2024 · Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) had its price objective trimmed by HC Wainwright from $78.00 to $38.00 in a research report report published on Monday morning, The Fly reports. WebApr 11, 2024 · Greenwich LifeSciences has a 1-year low of $6.82 and a 1-year high of $21.50. The business has a 50-day moving average price of $15.24 and a 200 day … crypto virtual wallet